Mark Glick, Ph.D. grew up in a Mennonite household in Indianapolis and attended a Mennonite college, Goshen College, but when he wanted a more advanced program in chemistry, Mark enrolled his senior year at IUPUI.
Mark then went to the University of Florida for his Ph.D. under the direction of Professor James Winefordner, a renowned leader in the use of lasers in spectrometry. Mark thought that he was going to be one of the later Ph.D. students (#92) in the group, but Dr. Winefordner supervised 169 Ph.D.s by the time he retired. Mark’s doctoral dissertation was in the esoteric field of Fourier transform spectrometry in the ultraviolet-visible region. With a plan to initiate a career in academic research, Mark then studied as a Merck Postdoctoral Fellow at IU Bloomington under the direction of another prolific leader in spectrometry, Professor Gary Hieftje.
With a vague sense that he was disappointing his mentors by not going into academic research, and a desire to stay in Indiana to be closer to family, Mark began a long career at Eli Lilly and Company, first as a bioanalytical chemist in Elanco, the animal health division, and last as the president of ImClone Systems in New Jersey, the oncology company that Lilly purchased in late 2008. Mark’s career at Lilly included roles in project management, in Lilly Diabetes, and in the oncology business unit. Mark was employed by Lilly until the end of 2017 when he, like many others, took early retirement. He then joined a biotech in NYC as the VP of Program Management for TG Therapeutics, a company developing therapies for patients with B-cell disorders, including leukemia, lymphoma, and multiple sclerosis.
Mark lives on the Upper West Side of Manhattan with his wife, Marci. When they aren’t working or attending theater in NYC, Mark skis in Vermont and bikes all over the city. They have three children and one daughter-in-law living in Charlottesville, Manhattan, and Indianapolis.